# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k113436   
B. Purpose for Submission: New device   
C. Measurand: Alkaline Phosphatase, Amylase, and Lactate Dehydrogenase   
D. Type of Test: Quantitative, enzymatic activity   
E. Applicant: Alfa Wassermann Diagnostic Technologies, LLC

# F. Proprietary and Established Names:

ACE Alkaline Phosphatase Reagent   
Amylase Reagent   
ACE LDH-L Reagent

# G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CJE</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>862.1050, Alkaline phosphataseor isoenzymes test system</td><td rowspan=1 colspan=1>75-Chemistry</td></tr><tr><td rowspan=1 colspan=1>CIJ</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>862.1070, Amylase test system</td><td rowspan=1 colspan=1>75-Chemistry</td></tr><tr><td rowspan=1 colspan=1>CFJ</td><td rowspan=1 colspan=1>II, exempt, meetslimitations ofexemption. 21 CFR862.9 (c) (4) and (9)</td><td rowspan=1 colspan=1>862.1440, Lactatedehydrogenase test system</td><td rowspan=1 colspan=1>75-Chemistry</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indication(s) for use:

The ACE Alkaline Phosphatase Reagent is intended for the quantitative determination of alkaline phosphatase activity in serum using the ACE Axcel Clinical Chemistry System. Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid and intestinal diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE Amylase Reagent is intended for the quantitative determination $\mathfrak { a }$ -amylase activity in serum using the ACE Axcel Clinical Chemistry System. Amylase measurements are used primarily for the diagnosis and treatment of pancreatitis (inflammation of the pancreas). This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE LDH-L Reagent is intended for the quantitative determination of lactate dehydrogenase activity in serum using the ACE Axcel Clinical Chemistry System. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction and tumors of the lung and kidneys. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

3. Special conditions for use statement(s): For in vitro diagnostic use only. For prescription and point-of-care use.

4. Special instrument requirements: ACE Axcel Clinical Chemistry System

# I. Device Description:

The ACE Alkaline Phosphatase Reagent and ACE LDH-L Reagent for the Axcel Clinical Chemistry System each come in a kit containing 6 liquid ready-to-use bottles; three bottles containing $3 0 ~ \mathrm { m L }$ of R1 (reagent 1), and three bottles containing $1 2 \mathrm { m L }$ of R2 or (reagent 2). The ACE Amylase Reagent for the Axcel Clinical Chemistry System comes in a kit containing 3 liquid ready-to-use bottles containing $3 0 ~ \mathrm { m L }$ of R1 (reagent 1). Buffers contain preservatives (sodium azide) and stabilizers.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

ACE Clinical Chemistry System, ACE Alkaline Phosphatase Reagent ACE Clinical Chemistry System, ACE Amylase Reagent ACE Clinical Chemistry System, ACE LDH-L Reagent

2. Predicate 510(k) number(s):

k931786

3. Comparison to predicate

Comparison for Alkaline Phosphatase (ALP):

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Candidate Device</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">510(k) #</td><td colspan="1" rowspan="1">k113436</td><td colspan="1" rowspan="1">k931786</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indicationsfor Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">ACE Alkaline Phosphatase Reagent isintended for the quantitative determination ofalkaline phosphatase activity in serum.</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzyme activity is directly determined bymultiplying the change in absorbance perminute of the unknown samples by aconstant factor based on the molarabsorbtivity of p-nitrophenoxide</td></tr><tr><td colspan="1" rowspan="1">MethodTraceability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Bowers, G.N. Jr. and McComb, R.B., Clin.Chem 12, 70 (1966); Tietz, N.W. et al., Clin.Chem. 29, 751 (1983).</td></tr><tr><td colspan="1" rowspan="1">Use ofControls</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Two levels of control per day</td></tr><tr><td colspan="1" rowspan="1">BasicPrinciple</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzymatic assay for alkaline phosphatase</td></tr><tr><td colspan="1" rowspan="1">MeasurementType</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Reaction of alkaline phosphatase withcolorless substrate (p-nitrophenylphosphate)in alkaline solution results in formation of p-nitrophenol and inorganic phosphate.measured spectrophotometrically at 408/486nm</td></tr><tr><td colspan="1" rowspan="1">ReactiveIngredients</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">p-Nitrophenyl phosphate, Magnesium salt,AMP buffer (pH 10.45)</td></tr><tr><td colspan="1" rowspan="1">Non-reactiveIngredients</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Preservatives and activators</td></tr><tr><td colspan="1" rowspan="1">Dimensions</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Bottles with total volumes of 12 and 30 mLof reagent</td></tr><tr><td colspan="1" rowspan="1">Analysis</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">37</td></tr><tr><td colspan="1" rowspan="1">Temperature</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">ReactionType</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Kinetic</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">SampleVolume</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">4 μL</td></tr><tr><td colspan="1" rowspan="1">ReactionVolume(total)</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">169 μL</td></tr><tr><td colspan="2" rowspan="1">Differences</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatforms</td><td colspan="1" rowspan="1">ACE Axcel Clinical ChemistrySystem</td><td colspan="1" rowspan="1">ACE and ACE Alera® Clinical ChemistrySystems</td></tr><tr><td colspan="1" rowspan="1">DetectionLimit</td><td colspan="1" rowspan="1">1.3 U/L</td><td colspan="1" rowspan="1">2 U/L</td></tr><tr><td colspan="1" rowspan="1">ReportableRange</td><td colspan="1" rowspan="1">9 to 1400 U/L</td><td colspan="1" rowspan="1">2 to 1400 U/L</td></tr><tr><td colspan="1" rowspan="2">EndogenousInterferences</td><td colspan="1" rowspan="1">Bilirubin: For the low pool, nosignificant interferenceoccurred below 27.95 mg/dL.Positive interference (19%)occurred at 55.9 mg/dL. Forthe high pool, no significantinterference occurred.Hemolysis: For the low pool,no significant interferenceoccurred below 62.5 mg/dL.Negative interference (≥16%)occurred at ≥125 mg/dL. Forthe high pool, no significantinterference occurred below500 mg/dL. A MXINIT flagoccurred at 1000 mg/dL forboth pools.Lipemia (Intralipid): For low</td><td colspan="1" rowspan="2">Bilirubin: No significant interference below12.5 mg/dL. Concentrations greater than 12.5may cause interference. Samples with 25mg/dL were found to positively interfere.Hemolysis: No significant interference below125 mg/dL. Concentrations greater than 125may cause interference. Samples with 250mg/dL were found to positively interfere.Lipemia (Intralipid): No significantinterference.</td></tr><tr><td colspan="1" rowspan="1">and high pools, no significantinterference occurred below1000 mg/dL. A MXINIT flagoccurred at 2000 mg/dL.Ascorbic Acid: No significantinterference.</td></tr><tr><td colspan="1" rowspan="1">Precision(U/L)</td><td colspan="1" rowspan="1">Within run:Sample A: Mean 50.0, SD 1.6,CV 3.2%Sample B: Mean 690.0, SD 9.8,</td><td colspan="1" rowspan="1">Within run:Sample A: Mean 42, SD 1.0, CV 2.4%Sample B: Mean 161, SD 2.5, CV 1.6%Sample C: Mean 332, SD 5.7, CV 1.7%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">CV 1.4%Sample C: Mean 1020.6, SD13.2, CV 1.3%Sample D: Mean 60.9, SD 1.6,CV 2.6%Total:Sample A: Mean 50.0, SD 2.2,CV 4.4%Sample B: Mean 690.0, SD19.9, CV 2.9%Sample C: Mean 1020.6, SD28.3, CV 2.8%Sample D: Mean 60.9, SD 2.9,CV 4.7%</td><td colspan="1" rowspan="1">Total:Sample A: Mean 42, SD 1.5, CV 3.6%Sample B: Mean 161, SD 4.3, CV 2.7%Sample C: Mean 332, SD 9.1, CV 2.7%</td></tr><tr><td colspan="1" rowspan="1">ComparativeAnalysisRegressionEvaluation</td><td colspan="1" rowspan="1">Regression Equation: y =0.983x + 0.6Correlation Coefficient of0.9997Sample Range: 12- 1363 U/L</td><td colspan="1" rowspan="1">Regression Equation: y = 0.984x -1.3Correlation Coefficient: 0.9995Sample Range: 14-1139 U/L</td></tr><tr><td colspan="1" rowspan="1">ExpectedValues</td><td colspan="1" rowspan="1">44-147 U/L</td><td colspan="1" rowspan="1">35-123 U/L</td></tr><tr><td colspan="1" rowspan="1">SampleStability</td><td colspan="1" rowspan="1">Serum ALP is stable for 7 daysat 2-8°C and for 3 months at -20</td><td colspan="1" rowspan="1">Serum ALP is stable for 7 days at 2-8°C andfor 3 months at -20°C</td></tr><tr><td colspan="1" rowspan="1">DetectionWavelength</td><td colspan="1" rowspan="1">408/486 nm</td><td colspan="1" rowspan="1">408/486 nm</td></tr><tr><td colspan="1" rowspan="1">ReagentStability</td><td colspan="1" rowspan="1">Unopened ACE AlkalinePhosphatase Reagent is stableuntil the expiration date shownon the box and bottle labelswhen stored in the refrigeratorat 2-8°C.</td><td colspan="1" rowspan="1">Unopened ACE Alkaline PhosphataseReagent is stable until the expiration dateshown on the box and bottle labels whenstored in the refrigerator at 2-8°C.</td></tr><tr><td colspan="1" rowspan="1">TestingEnvironment</td><td colspan="1" rowspan="1">Clinical laboratories orphysician office laboratories</td><td colspan="1" rowspan="1">Clinical laboratories or physician officelaboratories</td></tr></table>

Comparison for Amylase:   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Candidate Device</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">510(k) #</td><td colspan="1" rowspan="1">k113436</td><td colspan="1" rowspan="1">k931786</td></tr><tr><td colspan="2" rowspan="1">Similarities</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">ACE Amylase Reagent is intendedfor the quantitative determination of</td></tr><tr><td colspan="1" rowspan="1">for Use</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">α-amylase activity in serum</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzyme activity directly determinedby multiplying the change inabsorbance per minute of theunknown samples by a constantfactor based on the molarabsorbtivity of 2-chloro-p-nitrophenol</td></tr><tr><td colspan="1" rowspan="1">MethodTraceability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Tietz, N.W. (Ed.), Fundamentals ofClinical Chemistry, W.B. SaundersCo., Philadelphia, PA (1986);Sarber, R.L., Lishvin, L., Ramussen,J. and Blair, H.E., Clin. Chem. 32,1136 (1986).</td></tr><tr><td colspan="1" rowspan="1">Use ofControls</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Two levels of control per day</td></tr><tr><td colspan="1" rowspan="1">BasicPrinciple</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzymatic assay for α-amylase</td></tr><tr><td colspan="1" rowspan="1">MeasurementType</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Reaction of α-amylase withchromogenic substrate (2-chloro-p-nitrophenyl-α-D-maltotriosideresults in formation of 2-chloro-p-nitrophenol measuredspectrophotometrically at 408/647nm</td></tr><tr><td colspan="1" rowspan="1">ReactiveIngredients</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">2-Chloro-p-nitrophenyl-α-D-maltotriosidePotassium thiocyanateSodium chlorideCalcium acetateMES buffer (pH 6.0)</td></tr><tr><td colspan="1" rowspan="1">Non-reactiveIngredients</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Preservative</td></tr><tr><td colspan="1" rowspan="1">Dimensions</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Bottles with total volumes of 12 mLof reagent</td></tr><tr><td colspan="1" rowspan="1">AnalysisTemperature</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">37</td></tr><tr><td colspan="1" rowspan="1">ReactionType</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Kinetic</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">SampleVolume</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">3 μL</td></tr><tr><td colspan="1" rowspan="1">ReactionVolume</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">168 μL</td></tr><tr><td colspan="1" rowspan="1">(total)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">SampleStability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum amylase is stable for 7 daysat room temperature (18-26°C) andat 2-8°C for one month.Recommended storage is at 2-8°C.</td></tr><tr><td colspan="1" rowspan="1">DetectionWavelength</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">408/647 nm</td></tr><tr><td colspan="1" rowspan="1">TestingEnvironment</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Clinical laboratories or physicianoffice laboratories</td></tr><tr><td colspan="2" rowspan="1">Differences</td><td colspan="1" rowspan="1">EY</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatforms</td><td colspan="1" rowspan="1">ACE Axcel Clinical Chemistry System</td><td colspan="1" rowspan="1">ACE, ACE Alera® and NExCTTMClinical Chemistry Systems</td></tr><tr><td colspan="1" rowspan="1">DetectionLimit</td><td colspan="1" rowspan="1">8.5 U/L</td><td colspan="1" rowspan="1">0 U/L</td></tr><tr><td colspan="1" rowspan="1">ReportableRange</td><td colspan="1" rowspan="1">9 to 1900 U/L</td><td colspan="1" rowspan="1">0 to 1900 U/L</td></tr><tr><td colspan="1" rowspan="1">EndogenousInterferences</td><td colspan="1" rowspan="1">Bilirubin: For the low pool, nosignificant interference occurred below27.95 mg/dL. Positive interference(19%) occurred at 55.9 mg/dL. For thehigh pool, no significant interferenceoccurred.Hemolysis: For the low pool, nosignificant interference occurred below62.5 mg/dL. Negative interference(≥21%) occurred at ≥125 mg/dL. Forthe high pool, no significantinterference occurred.Lipemia (Intralipid): For low and highpools, no significant interferenceoccurred below 1000 mg/dL. AMXINIT flag occurred at 2000 mg/dL.Ascorbic Acid: No significantinterference.</td><td colspan="1" rowspan="1">Bilirubin: No significantinterference below 16.6 mg/dL.Concentrations greater than 16.6mg/dL may cause interference.Samples with 33.2 mg/dL werefound to positively interfere.Hemolysis: No significantinterference.Lipemia (Intralipid): No significantinterference.</td></tr><tr><td colspan="1" rowspan="1">Precision(U/L)</td><td colspan="1" rowspan="1">Within run:Sample A: Mean 50.7, SD 1.7, CV3.4%Sample B: Mean 849.2, SD 15.6, CV1.8%Sample C: Mean 1619.6, SD 24.2, CV1.5%Sample D: Mean 64.1, SD 1.7, CV2.6%</td><td colspan="1" rowspan="1">Within run:Sample A: Mean 53, SD 1.3, CV2.4%Sample B: Mean 112, SD 3.2, CV2.9%Sample C: Mean 444, SD 10.9, CV2.4%Total:Sample A: Mean 53, SD 2.2, CV</td></tr><tr><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">Total:Sample A: Mean 50.7, SD 1.8, CV3.6%Sample B: Mean 849.2, SD 16.8, CV2.0%Sample C: Mean 1619.6, SD 26.9, CV1.7%Sample D: Mean 64.1, SD 1.7, CV2.7%</td><td colspan="1" rowspan="1">4.1%Sample B: Mean 112, SD 3.5, CV3.1%Sample C: Mean 444, SD 10.5, CV2.4%</td></tr><tr><td colspan="1" rowspan="1">ComparativeAnalysisRegressionEvaluation</td><td colspan="1" rowspan="1">Regression Equation: y = 0.958x + 0.7Correlation Coefficient of 0.9997Sample Range: 11-1650 U/L</td><td colspan="1" rowspan="1">Regression Equation: y = 1.032x -5.2Correlation Coefficient: 0.9990Sample Range: 16-1444 U/L</td></tr><tr><td colspan="1" rowspan="1">ExpectedValues</td><td colspan="1" rowspan="1">20-104 U/L</td><td colspan="1" rowspan="1">25-125 U/L</td></tr></table>

Comparison for Alkaline Phosphatase (ALP):   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Candidate Device</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">510(k) #</td><td colspan="1" rowspan="1">k113436</td><td colspan="1" rowspan="1">k931786</td></tr><tr><td colspan="2" rowspan="1">Similarities</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indicationsfor Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">ACE LDH-L Reagent is intended forthe quantitative determination oflactate dehydrogenase activity inserum.</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzyme activity directly determinedby multiplying the change inabsorbance per minute of theunknown samples by a constantfactor based on the molarabsorptivity of NADH.</td></tr><tr><td colspan="1" rowspan="1">CalibrationStability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Not a calibrated test</td></tr><tr><td colspan="1" rowspan="1">MethodTraceability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Wacker, W.E.C., Ulmer, D.D,Vallee, B.L., New Engl. J. Med.,255, 449 (1956).</td></tr><tr><td colspan="1" rowspan="1">Use ofControls</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Two levels of control per day</td></tr><tr><td colspan="1" rowspan="1">BasicPrinciple</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Conversion of L-lactate to pyruvatewherein NAD is converted toNADH</td></tr><tr><td colspan="1" rowspan="1">MeasurementType</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">The rate of formation of NADHproduct is measured bichromaticallyat 340/647 nm.</td></tr><tr><td colspan="1" rowspan="1">ReactiveIngredients</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">L-lactateNicotinamide adenine dinucleotide</td></tr><tr><td colspan="1" rowspan="1">Non-reactiveIngredients</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Buffer, preservatives, stabilizers</td></tr><tr><td colspan="1" rowspan="1">AnalysisTemperature</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">37°</td></tr><tr><td colspan="1" rowspan="1">ReactionType</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Kinetic</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">SampleVolume</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">5 μL</td></tr><tr><td colspan="1" rowspan="1">ReactionVolume(total)</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">170 μL</td></tr><tr><td colspan="1" rowspan="1">ExpectedValues</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">100-190 U/L</td></tr><tr><td colspan="1" rowspan="1">SampleStability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Separated from cells, lactatedehydrogenase is stable for threedays at both 2-8°C and roomtemperature.</td></tr><tr><td colspan="1" rowspan="1">DetectionWavelength</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">340/647 nm</td></tr><tr><td colspan="1" rowspan="1">TestingEnvironment</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Clinical laboratories or physicianoffice laboratories</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatforms</td><td colspan="1" rowspan="1">ACE Axcel Clinical Chemistry System</td><td colspan="1" rowspan="1">ACE and ACE Alera® ClinicalChemistry Systems</td></tr><tr><td colspan="1" rowspan="1">DetectionLimit</td><td colspan="1" rowspan="1">8.3 U/L</td><td colspan="1" rowspan="1">17 U/L</td></tr><tr><td colspan="1" rowspan="1">ReportableRange</td><td colspan="1" rowspan="1">11 to 850 U/L</td><td colspan="1" rowspan="1">17 to 850 U/L</td></tr><tr><td>510(k) # Endogenous Interferences Precision</td><td>Candidate Device k113436 Bilirubin: No significant interference. Hemolysis: For the low pool, significant interference occurred at all levels tested. A HI LIN flag occurred at 1000 mg/dL. For the high pool, no significant interference occurred below 31.25 mg/dL. Positive interference (≥12%) occurred at ≥62.5 mg/dL. A HI LIN flag occurred at 500 mg/dL. A DEPL flag occurred at 1000 mg/dL. Hemolysis of red cells release lactate dehydrogenase into the sample. Do not use hemolyzed samples. Triglycerides: No significant interference. Ascorbic Acid: No significant interference.</td><td>Predicate Device k931786 Bilirubin: No significant interference. Hemolysis: Positive interference at 31 mg/dL Lipemia (Intralipid): Positive interference at 500 mg/dL Triglycerides: No significant interference below 460 mg/dL Ascorbic Acid: No significant interference Lactic Acid: No significant interference</td></tr><tr><td>(U/L)</td><td>Within run: Sample A: Mean 130.5, SD 3.0, CV 2.3% Sample B: Mean 437.4, SD 7.1, CV 1.6% Sample C: Mean 720.6, SD 11.8, CV 1.6% Sample D: Mean 94.7, SD 2.9, CV 3.1% Total: Sample A: Mean 130.5, SD 4.1, CV 3.2% Sample B: Mean 437.4, SD 10.2, CV 2.3% Sample C: Mean 720.6, SD 16.5, CV 2.3% Sample D: Mean 94.7, SD 4.3, CV 4.6%</td><td>Within Run: Sample A: Mean 82, SD 5.1, CV 6.2% Sample B: Mean 122, SD 5.7, CV 4.7% Sample C: Mean 282, SD 4.6, CV 1.6% Sample D: Mean 680, SD 9.7, CV 1.4% Total: Sample A: Mean 82, SD 7.0, CV 8.5% Sample B: Mean 122, SD 7.7, CV 6.3% Sample C: Mean 282, SD 10.6, CV 3.8% Sample D: Mean 680, SD 18.4, CV 2.7%</td></tr><tr><td>Comparative Analysis Regression Evaluation</td><td>Regression Equation: y = 1.046x + 4.9 Correlation Coefficient of 0.9986 Sample Range: 22-829 U/L</td><td>Regression Equation: y = 0.965x + 0.7 Correlation Coefficient: 0.9994 Sample Range: 20-800 U/L</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition   
CLSI EP6-A: Evaluation of Linearity of Quantitative Measurement Procedures, A Statistical Approach; Approved Guideline   
CLSI EP7-A2: Interference Testing in Clinical Chemistry; Approved Guideline-Second Edition   
CLSI EP9-A2-IR: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Second Edition   
CLSI EP10-A3: Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline-Third Edition   
CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of   
Quantitation; Approved Guideline

# L. Test Principle:

The ACE Alkaline Phosphatase Reagent for the Axcel Clinical Chemistry System is an enzymatic photometric test; alkaline phosphatase in serum catalyzes the hydrolysis of the pnitrophenyl phosphate substrate to produce inorganic phosphate and $\mathfrak { p }$ -nitrophenol product which is measured at $4 0 8 \mathrm { n m }$ . The rate of increase of absorbance is directly proportional to the amount of alkaline phosphatase activity in the serum sample.

![](images/09834d91750926609b0bf59ea3a8805145198e398c29328c1af90089fa021250.jpg)

The ACE Amylase Reagent for the Axcel Clinical Chemistry System is an enzymatic photometric test; $\mathfrak { a }$ -amylase in serum catalyzes the reaction of the maltotrios-linked 2-chloro$\mathfrak { p }$ -nitrophenol phosphate substrate to produce 2-chloro-p-nitrophenol product which is measured at $4 0 8 { \mathrm { n m } }$ . The rate of increase of absorbance is directly proportional to the amount of amylase activity in the serum sample.

The ACE LDH-L Reagent for the Axcel Clinical Chemistry System is an enzymatic photometric test; LDH in serum catalyzes the conversion of the L-lactate and NAD substrates to pyruvate and NADH, and the NADH product which is measured at $3 4 0 \mathrm { n m }$ . The rate of increase of absorbance from the formation of NADH is directly proportional to the amount of LDH activity in the serum sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

In-house precision   

<table><tr><td rowspan=1 colspan=2>Precision studies wereconducted by testing humanserum pools at four levels. Thesamples were run 2 times perrun, 2 runs per day, for a totalof 20 days using oneinstrument. Results aresummarized below.AlkalinePhosphatase</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>50.0</td><td rowspan=1 colspan=1>690.0</td><td rowspan=1 colspan=1>1020.6</td><td rowspan=1 colspan=1>60.9</td></tr><tr><td rowspan=2 colspan=1>Within Run</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=2 colspan=1>Between Run</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=2 colspan=1>Between Day</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=1>24.0</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=2 colspan=1>Total</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>28.3</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.7</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Amylase</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>50.7</td><td rowspan=1 colspan=1>849.2</td><td rowspan=1 colspan=1>1619.6</td><td rowspan=1 colspan=1>64.1</td></tr><tr><td rowspan=2 colspan=1>Within Run</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>24.2</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=2 colspan=1>Between Run</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>00.0</td></tr><tr><td rowspan=2 colspan=1>Between Day</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=2 colspan=1>Total</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>16.8</td><td rowspan=1 colspan=1>26.9</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.7</td></tr></table>

<table><tr><td colspan="2" rowspan="1">LDH</td><td colspan="1" rowspan="1">Sample 1</td><td colspan="1" rowspan="1">Sample 2</td><td colspan="1" rowspan="1">Sample 3</td><td colspan="1" rowspan="1">Sample 4</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Mean (U/L)</td><td colspan="1" rowspan="1">130.5</td><td colspan="1" rowspan="1">437.4</td><td colspan="1" rowspan="1">720.6</td><td colspan="1" rowspan="1">94.7</td></tr><tr><td colspan="1" rowspan="2">Within Run</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">11.8</td><td colspan="1" rowspan="1">2.9</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">3.1</td></tr><tr><td colspan="1" rowspan="2">Between Run</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="2">Between Day</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">10.9</td><td colspan="1" rowspan="1">2.6</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">2.8</td></tr><tr><td colspan="1" rowspan="2">Total</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">10.2</td><td colspan="1" rowspan="1">16.5</td><td colspan="1" rowspan="1">4.3</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">4.6</td></tr></table>

# Point-of-Care precision

Precision studies were also conducted at three Physician Office Laboratories (POL) with four trained operators typically found in these settings. Human serum pools at three concentrations were tested three times a day for five days on three instruments (one at each lab). The results are presented below:

<table><tr><td rowspan=1 colspan=3>Alkaline Phosphatase</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>49.9</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>49.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>48.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>679.5</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>31.8</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>664.7</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>676.1</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>27.5</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1340.9</td><td rowspan=1 colspan=1>20.7</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>43.7</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1293.4</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>56.3</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1041.0</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>21.2</td><td rowspan=1 colspan=1>2.0</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Amylase</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>53.3</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>55.0</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>908.9</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>16.1</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>872.7</td><td rowspan=1 colspan=1>30.9</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>41.6</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>945.6</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1749.3</td><td rowspan=1 colspan=1>25.0</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>41.7</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1669.1</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>30.9</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1782.5</td><td rowspan=1 colspan=1>16.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>16.9</td><td rowspan=1 colspan=1>0.9</td></tr></table>

<table><tr><td colspan="3" rowspan="1">LDH</td><td colspan="2" rowspan="1">Within Run</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Lab</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Mean (U/L)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">POL 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">126.1</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">2.5</td></tr><tr><td colspan="1" rowspan="1">POL 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">132.3</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">POL 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">130.9</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">POL 1</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">420.8</td><td colspan="1" rowspan="1">12.6</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">13.8</td><td colspan="1" rowspan="1">3.3</td></tr><tr><td colspan="1" rowspan="1">POL 2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">442.1</td><td colspan="1" rowspan="1">8.3</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">8.3</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">POL 3</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">442.1</td><td colspan="1" rowspan="1">6.8</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">POL 1</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">701.1</td><td colspan="1" rowspan="1">9.6</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">12.4</td><td colspan="1" rowspan="1">1.8</td></tr><tr><td colspan="1" rowspan="1">POL 2</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">727.2</td><td colspan="1" rowspan="1">15.2</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">18.9</td><td colspan="1" rowspan="1">2.6</td></tr><tr><td colspan="1" rowspan="1">POL 3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">738.3</td><td colspan="1" rowspan="1">8.4</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">12.3</td><td colspan="1" rowspan="1">1.7</td></tr></table>

# b. Linearity/assay reportable range:

Linearity across the assay range was confirmed by spiking serum samples to a high concentration of analyte, then diluting the sample to obtain between 12 and 15 levels to cover the measuring range of each assay. The assigned value of the highest sample was set to its mean value. The assigned values of the other levels were calculated by multiplying the mean value by the dilution ratios obtained from the manufacturer. Each level was tested in replicates of four. Data was analyzed to show linear regression equations and also the $2 ^ { \mathrm { n d } }$ and $3 ^ { \mathrm { r d } }$ polynomial equations, and all data demonstrated that the 3 devices were linear across the claimed measuring range. Results are presented below:

Alkaline Phosphatase Linear Regression: $\mathbf { y } = 0 . 9 7 3 \mathbf { x } - 1 . 3$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 7 6$ $2 ^ { \mathrm { n d } }$ Order: $\mathbf { y } = 0 . 0 0 0 0 3 6 \mathbf { x } ^ { 2 } + 0 . 9 2 5 \mathbf { x } + 4 . 2 8$ $3 ^ { \mathrm { r d } }$ Order: $\dot { \mathbf { y } } = 0 . 0 0 0 0 0 0 0 1 \mathbf { x } ^ { 3 } - 0 . 0 0 0 1 3 \mathbf { x } ^ { 2 } + 1 . 0 1 \mathbf { x } - 0 . 2 6 0$ Claimed measuring range: $9 - 1 4 0 0 \mathrm { U / L }$

Amylase Linear Regression: $\mathrm { y } = 1 . 0 0 6 \mathrm { x } + 4 . 8 .$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 9 5$ $2 ^ { \mathrm { n d } }$ Order: $\mathrm { y } = 0 . 0 0 0 0 1 \mathrm { x } ^ { 2 } + 1 . 0 4 1 \mathrm { x } - 1 . 6 2$ $3 ^ { \mathrm { r d } }$ Order: $\mathrm { y } = - 0 . 0 \mathrm { x } ^ { 3 } + 0 . 0 0 0 0 0 1 3 \mathrm { x } ^ { 2 } + 1 . 0 3 \mathrm { x } - 0 . 4 6 0$ Claimed measuring range: $9 - 1 9 0 0 \mathrm { U l / L }$

LDH Linear Regression: $\mathrm { y } = 1 . 0 1 5 \mathrm { x } + 7 . 3 6$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 8 0$ $2 ^ { \mathrm { n d } }$ Order: $\mathrm { y } = 0 . 0 0 0 1 1 2 \mathrm { x } ^ { 2 } + 1 . 1 1 \mathrm { x } - 1 . 5 1$ $3 ^ { \mathrm { r d } }$ Order: $\dot { \mathbf { y } } = - 0 . 0 0 0 0 0 0 0 2 { \mathbf { x } } ^ { 3 } + 0 . 0 0 0 1 9 4 { \mathbf { x } } ^ { 2 } + 1 . 0 1 \mathbf { x } + 2 . 6 5$ Claimed measuring range: $1 1 - 8 5 0 \mathrm { U / L }$

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability:

Calibration of the LDH-L assay is traceable to a frozen Master Pool of verification material utilized by the reagent supplier. Each lot of reagent is tested by running the Master Pool and verifying that results of the Master Pool levels are within an acceptable percentage of the assigned values of the Master Pool. For value assignment, each new verification Master Pool is made by gravimetrically adding quantities of lactate dehydrogenase to a serum pool to target concentrations. Five levels of Master Pool are prepared, aliquoted and stored at $\le - 7 0 ^ { \circ } \mathrm { C }$ . The final values of the Master Pool are assigned for each level by testing at least 3 replicates on multiple instruments. The activity levels of the new Master Pool are verified using a previously approved Master Pool lot as a control.

The ACE Alkaline Phosphatase and Amylase reagents are traceable to an IFCC traceable method, using a linearity verification set with various levels run in triplicate and assessed for linearity versus the assigned values from the linearity set.

# d. Detection limit:

The limit of detection and the limit of the blank were determined by assaying five low samples (serum samples) and five true blanks (human serum albumin in saline). Testing was carried out over three days on two ACE Axcel Clinical Chemistry Analyzers. Serum samples and true blanks were assayed every day for a total of 60 measurements. The limit of quantitation was determined with 40 replicates of 3 low samples, and was determined to be the mean when the $\% \mathrm { C V }$ was $\leq 2 0 \%$ .

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>LoB (U/L)</td><td rowspan=1 colspan=1>LoD (U/L)</td><td rowspan=1 colspan=1>LoQ (U/L)</td></tr><tr><td rowspan=1 colspan=1>Alkaline Phosphatase</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Amylase</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>LDH</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>11</td></tr></table>

# e. Analytical specificity:

Interference studies were performed to determine the effects from potential interferents. The various concentrations of interferent were spiked into serum pools containing alkaline phosphatase, amylase and LDH at normal and abnormal concentrations. Hemolysis was simulated using a freeze-thaw method to lyse the red cells. All samples were tested in triplicate. Seven levels were tested for each interferent. Significant interference was defined as a difference in analyte recovery of more than $\pm 1 0 \%$ .

Alkaline Phosphatase:   

<table><tr><td>Interferent Compound</td><td>Concentration with No Interference Up To</td></tr><tr><td>Ascorbic Acid</td><td>6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Unconjugated Bilirubin</td><td colspan="1" rowspan="1">28 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Hemolysis (hemoglobin)</td><td colspan="1" rowspan="1">62.5 mg/dL*</td></tr><tr><td colspan="1" rowspan="1">Intralipid</td><td colspan="1" rowspan="1">500 mg/dL</td></tr></table>

Amylase:   

<table><tr><td rowspan=1 colspan=1>Interferent Compound</td><td rowspan=1 colspan=1>Concentration with NoInterferenceUp To</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>28 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis (hemoglobin)</td><td rowspan=1 colspan=1>62.5 mg/dL*</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr></table>

LDH:   

<table><tr><td rowspan=1 colspan=1>Interferent Compound</td><td rowspan=1 colspan=1>Concentration with NoInterference Up To</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>62 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis (hemoglobin)</td><td rowspan=1 colspan=1>Interference at All Levels*</td></tr><tr><td rowspan=1 colspan=1>Triglycerides**</td><td rowspan=1 colspan=1>2620 mg/dL</td></tr></table>

\*The package insert contains the following statement: Do not use hemolyzed samples.

\*\*Triglycerides were used in the study with LDH as the sponsor suspected matrix interferences from intralipid with this analyte.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

An in-house method comparison study to the predicate device was performed with serum patient samples. A total of 113 alkaline phosphatase (103 native, 5 diluted and 5 spiked) serum samples, 111 amylase (101 native, 4 diluted and 6 spiked) serum sample, and 121 LDH (109 native, 5 dilutes and 7 spiked) serum samples covering the assay range were tested. The results are presented in the table below:

<table><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">RegressionEquation</td><td colspan="1" rowspan="1">r2}$</td><td colspan="1" rowspan="1">StandardError</td><td colspan="1" rowspan="1">Sample range(U/L)</td></tr><tr><td colspan="1" rowspan="1">AlkalinePhosphatase</td><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">y=0.983x+0.6</td><td colspan="1" rowspan="1">0.9997</td><td colspan="1" rowspan="1">5.1</td><td colspan="1" rowspan="1">12-1363</td></tr><tr><td colspan="1" rowspan="1">Amylase</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">y=0.958x+0.7</td><td colspan="1" rowspan="1">0.9997</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">11-1650</td></tr><tr><td colspan="1" rowspan="1">LDH</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">y=1.046x+4.9</td><td colspan="1" rowspan="1">0.9986</td><td colspan="1" rowspan="1">7.5</td><td colspan="1" rowspan="1">22-829</td></tr></table>

Additional method comparison studies were performed at three Physician Office Laboratories, with four operators. Operators assayed serum samples ranging from 11- $1 3 8 8 \mathrm { U / L }$ alkaline phosphatase, $1 2 { \cdot } 1 8 5 6 \ \mathrm { U } / \mathrm { L }$ amylase, and $1 8 { - } 8 1 9 \mathrm { L D H }$ on the Ace Axcel clinical chemistry analyzer and the ACE clinical chemistry System. The results are presented in the tables below:

Alkaline Phosphatase   

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>r2}$</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>Sample range(U/L)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>y=1.040x+3.5</td><td rowspan=1 colspan=1>0.9957</td><td rowspan=1 colspan=1>25.3</td><td rowspan=1 colspan=1>11-1311</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>y=0.972x+1.5</td><td rowspan=1 colspan=1>0.9998</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>49-1261</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>y=1.000x+8.7</td><td rowspan=1 colspan=1>0.9983</td><td rowspan=1 colspan=1>16.8</td><td rowspan=1 colspan=1>26-1388</td></tr></table>

Amylase   

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>r2 }$</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>Sample range(U/L)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>y=0.997x-2.5</td><td rowspan=1 colspan=1>0.9998</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>12-1819</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>y=0.984x-0.5</td><td rowspan=1 colspan=1>0.9985</td><td rowspan=1 colspan=1>22.3</td><td rowspan=1 colspan=1>19-1856</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>y=1.019x-1.5</td><td rowspan=1 colspan=1>1.0000</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>18-1797</td></tr></table>

LDH   

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>r2 }$</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>Sample range(U/L)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>y=1.010x-1.1</td><td rowspan=1 colspan=1>0.9983</td><td rowspan=1 colspan=1>13.1</td><td rowspan=1 colspan=1>33-819</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>y=1.042x-5.7</td><td rowspan=1 colspan=1>0.9993</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>18-773</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>y=1.011x+2.6</td><td rowspan=1 colspan=1>0.9988</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>22-787</td></tr></table>

b. Matrix comparison:

The device is being cleared for serum use only.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable. Clinical studies are not typically submitted for this device type.

5. Expected values/Reference range:

The reference range for each analyte was verified according to CLSI C28-A3. 50 normal healthy patient samples from a diverse population with an age range from 20 to 60, were each analyzed for ALP, Amylase, and LDH. The $9 5 \%$ confidence intervals were calculated and the reference range was shown to validate the reference range stated in the literature ( for amylase and LDH: Tietz Clinical Guide to Laboratory Tests, $4 ^ { \mathrm { t h } }$ Ed, Wu et $a l$ ; for ALP: Medline Plus reference range data base, U.S. National Library of Medicine, National Institutes of Health).

ALP: 44 – 147 U/L Amylase: 20 – 104 U/L LDH: 100 – 190 U/L

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.